Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
08 sept. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...